FrancophonIA/ELRC3.0 huggingface dataset:
English: The doctor will also check your kidney and liver function before starting the infusion.
Estonian: Lisaks kontrollib arst enne protseduuriga alustamist ka teie maksa- ning neerufunktsiooni.
English: LysaKare is indicated for administration with PRRT with lutetium (177Lu) oxodotreotide therefore, it should only be administered by a health care provider experienced in the use of PRRT.
Estonian: Lu)-oksodotreotiidiga PRRT ajal, seetõttu tohib seda manustada ainult tervishoiuteenuse osutaja, kellel on kogemusi PRRT kasutamisega.
English: Each infusion bag contains 25 g of L-arginine hydrochloride and 25 g of L-lysine hydrochloride.
Estonian: Iga infusioonikott sisaldab 25 g arginiinvesinikkloriidi ja 25 g lüsiinvesinikkloriidi.
English: A dosimetry study including 6 patients showed that a 2.5% Lysine-Arginine amino acid solution reduced renal radiation exposure by about 47% as compared to no treatment, without having an effect on tumour uptake of lutetium (177Lu) oxodotreotide.
Estonian: Dosimeetriauuring 6 patsiendiga näitas, et 2,5% lüsiini-arginiini aminohappelahus vähendas neerude kiirgusega kokkupuudet umbes 47% võrreldes kontrollidega, mõjutamata luteetsium-(
English: • high potassium levels seen in blood tests, abdominal (belly) pain, headache, dizziness and flushing.
Estonian: Teadmata (sagedust ei saa hinnata olemasolevate andmete põhjal): • kõrged kaaliumisisaldused vereanalüüsides, kõhuvalu, peavalu, pearinglus ja õhetus.
English: Pre-treatment with an anti-emetic 30 minutes prior to start of LysaKare infusion is recommended to reduce the incidence of nausea and vomiting.
Estonian: Iivelduse ja oksendamise esinemissageduse vähendamiseks on soovitatav 30 minutit enne LysaKare'i infusiooni alustamist teostada eelravi antiemeetikumiga.
English: How to store LysaKare
Estonian: Kuidas LysaKare'i säilitada
English: You will receive LysaKare in a controlled clinical setting.
Estonian: Te saate LysaKare'i tervishoiuasutuses.
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING Polyvinyl chloride (PVC) infusion bag
Estonian: Polüvinüülkloriid (PVC) infusioonikott
English: NAME OF THE MEDICINAL PRODUCT LysaKare 25 g/25 g solution for infusion
Estonian: LysaKare 25 g/25 g infusioonilahus
English: ANNEX II
Estonian: Tabel 1
English: QUALITATIVE AND QUANTITATIVE COMPOSITION One 1,000 mL bag contains 25 g of L-arginine hydrochloride and 25 g of L-lysine hydrochloride.
Estonian: Üks 1000 ml kott sisaldab 25 g arginiinvesinikkloriidi ja 25 g lüsiinvesinikkloriidi.
English: Treatment with lutetium (177Lu) oxodotreotide is not recommended for patients with renal function between 30 and 50 mL/min therefore, the benefit risk for these patients will always need to be weighed carefully, which should include consideration of an increased risk for transient hyperkalaemia in these patients (see section 4.4).
Estonian: Lu)-oksodotreotiidi manustamine pole neile patsientidele soovitatav, mistõttu tuleks kasu riski suhet hoolikalt kaaluda, arvestades mööduva hüperkaleemia riski (vt lõik 4.4).
English: Patiens with hepatic impairment
Estonian: Neerukahjustusega patsiendid
English: The overwrap is a moisture barrier.
Estonian: Ümbris kaitseb niiskuse eest.
English: The use of arginine and lysine has not been specifically studied in patients with renal impairment.
Estonian: Neerukahjustusega patsientidel ei ole spetsiifiliselt uuritud arginiini ja lüsiini kasutamist.
English: LysaKare and lutetium (177Lu) oxodotreotide must be given through a separate infusion line.
Estonian: Lu)-oksodotreotiidi tuleb manustada eraldi infusiooniliini kaudu.
English: An increase of serum potassium levels may occur in patients receiving arginine and lysine.
Estonian: Arginiini ja lüsiini saavatel patsientidel võib tõusta kaaliumisisaldus seerumis.
English: NAME OF THE MEDICINAL PRODUCT LysaKare 25 g/25 g solution for infusion L-arginine hydrochloride/L-lysine hydrochloride
Estonian: LysaKare 25 g/25 g infusioonilahus arginiinvesinikkloriid/ lüsiinvesinikkloriid
English: What LysaKare is and what it is used for 2.
Estonian: 1. Mis ravim on LysaKare ja milleks seda kasutatakse 2. Mida on vaja teada enne LysaKare'i võtmist 3.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING Polyethylene polyamine/aluminium foil
Estonian: Polüetüleenpolüamiin/alumiiniumfoolium
English: Breast-feeding should be avoided during treatment with lutetium (177Lu) oxodotreotide.
Estonian: Lu)-oksodotreotiidiga ravi ajal tuleb rinnaga toitmist vältida.
English: • Pre-existing clinically significant hyperkalaemia if not adequately corrected before starting the
Estonian: • Kliiniliselt oluline hüperkaleemia, kui see on enne LysaKare infusiooniga alustamist korrigeerimata (vt lõik 4.4).
English: LysaKare is used in adult patients to protect kidneys from unnecessary radiation during treatment with Lutathera (lutetium (177Lu) oxodotreotide), a radioactive medicine used to treat certain tumours.
Estonian: LysaKare'i kasutatakse täiskasvanud patsientidel, et kaitsta neerusid mittevajaliku kiirguse eest ravi ajal Lutathera-ga (luteetsium-(
English: Tabulated list of adverse reactions
Estonian: Tabelisse kantud kõrvaltoimete loetelu
English: 6.3 Shelf life
Estonian: 6.3 Säilitusaeg
English: PHARMACEUTICAL FORM AND CONTENTS Solution for infusion
Estonian: RAVIMVORM JA PAKENDI SISU
English: OTHER SPECIAL WARNING(S), IF NECESSARY Do not reconnect partially used bags.
Estonian: TEISED ERIHOIATUSED (VAJADUSEL)
English: Adverse drug reaction
Estonian: Ravimi kõrvaltoimed
English: What LysaKare is
Estonian: Mis ravim on LysaKare
English: The recommended treatment regimen in adults consists of infusion of full bag of LysaKare concomitantly with lutetium (177Lu) oxodotreotide infusion, even when patients require PRRT dose reduction.
Estonian: Lu)-oksodotreotiidi infusiooniga, isegi kui patsiendid vajavad PRRT annuse vähendamist.
English: BATCH NUMBER Lot:
Estonian: MÜÜGILOA NUMBER (NUMBRID)
English: The risk caused by radioactivity is thought to be very low.
Estonian: Radioaktiivsuse riski loetakse väga väikeseks.
English: It must not be used in women who are pregnant.
Estonian: Ravimit ei tohi kasutada rasedatel.
English: The European Commission granted a marketing authorisation valid throughout the European Union for DaTSCAN to GE Healthcare Limited on 27 July 2000.
Estonian: Euroopa Komisjon andis DaTSCANi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele GE Healthcare Limited 27. juulil 2000.
English: This summary was last updated in 04-2011.
Estonian: Kokkuvõtte viimane uuendus: 07-2010.
English: DaTSCAN is only handled and given by people who have experience in the safe handling of radioactive materials.
Estonian: DaTSCANi on lubatud käsitseda ja manustada ainult inimestel, kellel on radioaktiivsete materjalide ohutu käsitsemise kogemus.
English: DaTSCAN is given by slow injection lasting no less than 15 to 20 seconds into an arm vein.
Estonian: DaTSCANi manustatakse aeglase vähemalt 15-20-sekundilise süstina käsivarreveeni.
English: DaTSCAN is for diagnostic use only.
Estonian: DaTSCAN on ette nähtud kasutamiseks üksnes diagnostikas.
English: In the larger of the two studies, the sensitivity of DaTSCAN was 97%.
Estonian: Suuremas uuringus oli DaTSCANi tundlikkus 97%.
English: In movement disorders, DaTSCAN has been studied in 254 adults in two main studies.
Estonian: Liikumishäirete korral uuriti DaTSCANi kahes põhiuuringus 254 täiskasvanul.
English: A scan is taken three to six hours after the injection.
Estonian: Uuring tehakse 3-6 tundi pärast süstimist.
English: The CHMP decided that DaTSCAN's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et DaTSCANi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The medicine is used to help in the diagnosis of the following conditions in adults (aged 18 years or over):
Estonian: Ravim aitab diagnoosida vähemalt 18-aastastel täiskasvanutel järgmisi haigusi:
English: This document is a summary of the European public assessment report (EPAR) for DaTSCAN.
Estonian: Käesolev dokument on ravimi DaTSCAN Euroopa avaliku hindamisaruande kokkuvõte.
English: This means that the disease identified by the doctor reading the images obtained using DaTSCAN matched the existing diagnosis of the patients in 97% of cases.
Estonian: See tähendab, et DaTSCANi kasutamisel vastas pilte hinnanud arsti poolt kindlaksmääratud haigus 97% juhtudest patsientide olemasolevale diagnoosile.
English: In movement disorders, DaTSCAN was effective at detecting changes in the brain due to Parkinson's disease or related diseases.
Estonian: Liikumishäirete korral oli DaTSCAN efektiivne Parkinsoni tõve või seotud haiguste tekitatud ajumuutuste tuvastamisel.
English: ioflupane (123I)
Estonian: ioflupaan ()
English: For more information about treatment with DaTSCAN, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate DaTSCANiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: In all of the studies, the main measure of effectiveness was the accuracy of the diagnosis based on the images from the scan compared with the diagnosis made by a specialist doctor.
Estonian: Kõikides uuringutes oli efektiivsuse põhinäitaja tomograafiapiltide põhjal tehtud diagnoosi täpsus võrreldes eriarsti diagnoosiga.
English: In the studies, images obtained in 45 healthy volunteers were compared with those obtained in 180 patients with Parkinson's disease or related diseases, and in 29 patients with essential tremor.
Estonian: Nendes uuringutes võrreldi tervetelt vabatahtlikelt (kokku 45) saadud pilte Parkinsoni tõvega patsientidelt (180 patsienti) või essentsiaalse treemoriga (29 patsienti) patsientidelt saadud piltidega.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for DaTSCAN.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: This can be seen using a special imaging technique called single-photon-emission computed tomography (SPECT), which detects the radioactive iodine-123.
Estonian: Seondumist võib näha spetsiaalse pildindustehnikaga, üksikfootoni kompuuteremissioontomograafiaga (SPECT), kus tuvastatakse radioaktiivne jood-123.
English: This enables diseases related to Parkinson's disease to be distinguished from essential tremor, and for Lewy body dementia to be distinguished from Alzheimer's disease.
Estonian: See võimaldab eristada Parkinsoni tõvega soetud haigusi essentsiaalsest treemorist ning Lewy kehadega dementsust Alzheimeri tõvest.
English: This is taken one to four hours before DaTSCAN.
Estonian: Seda võetakse 1-4 tundi enne ja seejärel 12-24 tundi pärast DaTSCANi.
English: In dementia, DaTSCAN has been studied in one main study involving 288 adults who had been diagnosed with dementia with Lewy bodies or Alzheimer's disease, or another form of dementia.
Estonian: DaTSCANi kasutamist dementsuse korral uuriti 288 patsiendil, kellel oli diagnoositud kas Lewy kehadega dementsus või Alzheimeri tõbi või mõni muu dementsuse vorm.
English: Why has DaTSCAN been approved?
Estonian: Miks DaTSCAN heaks kiideti?
English: • movement disorders such as those seen in Parkinson's disease and other related diseases, where a loss of nerve cells leads to tremor (shaking), gait disturbance (problems with the way the patient walks) and stiffness of the muscles.
Estonian: • liikumishäired, näiteks Parkinsoni tõve ja muude sellega seotud haiguste korral, kus närvirakkude hävimine põhjustab värinat, kõnnakuhäireid ja lihaste jäikust.
English: When receiving DaTSCAN, patients must also take another medicine, such as iodine tablets, to prevent their thyroid gland from taking up the iodine contained in DaTSCAN.
Estonian: DaTSCANi saavad patsiendid peavad võtma ka muud ravimit (näiteks jooditablette), et DaTSCANis sisalduv jood ei neelduks kilpnäärmes.
English: Because tremor can also occur in ‘essential tremor' (tremor whose cause is unknown), DaTSCAN is used to help distinguish between essential tremor and diseases related to Parkinson's disease;
Estonian: et samu häireid võib aga esineda ka essentsiaalse (teadmata põhjusega) treemori korral, kasutatakse DaTSCANi Parkinsoni tõve eristamiseks essentsiaalsest treemorist;
English: For the full list of all side effects reported with DaTSCAN, see the package leaflet.
Estonian: DaTSCANi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: DaTSCAN should not be used in people who may be hypersensitive (allergic) to ioflupane or any of the other ingredients.
Estonian: DaTSCANi ei tohi kasutada patsiendid, kes võivad olla ioflupaani või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: It contains a substance called ioflupane, which is labelled with 123I (iodine-123), a radioactive form of the chemical element iodine.
Estonian: See sisaldab ioflupaani, mis on märgistatud 123I-ga (jood-123), mis on keemilise elemendi joodi radioaktiivne isotoop.
English: Ioflupane attaches specifically to structures on the surface of nerve cell endings in the striatum that are responsible for the transport of dopamine.
Estonian: Ioflupaan seondub aju juttkeha piirkonna närvirakkude lõpmete pinnal olevate struktuuridega, mille ülesanne on dopamiini transportimine.
English: What is DaTSCAN?
Estonian: Mis on DaTSCAN?
English: What is the risk associated with DaTSCAN?
Estonian: Mis riskid DaTSCANiga kaasnevad?
English: When DaTSCAN is injected, ioflupane (123I) is distributed through the body in the blood and accumulates in the striatum, where it attaches to the structures that transport dopamine.
Estonian: DaTSCANi süstimisel patsiendile levib ioflupaan (123I) organismis vereringega laiali ja koguneb juttkehasse, kus seondub struktuuridega, mille ülesanne on dopamiini transportimine.
English: Other information about DaTSCAN:
Estonian: Muu teave DaTSCANi kohta
English: DaTSCAN should only be used in patients who have been referred by a doctor with experience in the management of movement disorders or dementia.
Estonian: DaTSCANi võib kasutada ainult liikumishäirete või dementsuse ravi kogemusega arsti suunatud patsientidel.
English: The active substance in DaTSCAN, ioflupane (123I), is a radiopharmaceutical.
Estonian: DaTSCANi toimeaine ioflupaan (123I) on radiofarmatseutiline aine.
English: What is DaTSCAN used for?
Estonian: Milleks DaTSCANi kasutatakse?
English: In patients with Parkinson's disease and related diseases, and in patients with dementia with Lewy bodies, there is typically a loss of nerve cells in the striatum containing dopamine.
Estonian: Dopamiini sisaldavate närvirakkude hävimisel (nagu see on tüüpiline Parkinsoni tõvega ja seotud haigustega ning Lewy kehadega dementsusega patsientidel) DaTSCANiga seondumine tunduvalt väheneb ja seda on tomograafiapildil näha.
English: The most common side effect with DaTSCAN (seen in between 1 and 10 patients in 100) is headache.
Estonian: DaTSCANi kõige sagedamad kõrvalnähud (esinenud 1-10 patsiendil 100st) on söögiisu suurenemine, peavalu, kirvendus (nn sipelgate jooksmise tunne) ja vertiigo (peapööritus).
English: What benefit has DaTSCAN shown during the studies?
Estonian: Milles seisneb uuringute põhjal DaTSCANi kasulikkus?
English: Resuscitation equipment should be available before DaTSCAN is given, in case the patient has an allergic reaction.
Estonian: Et patsiendil võib tekkida allergiline reaktsioon, peavad enne DaTSCANi manustamist olema olemas elustusseadmed.
English: DaTSCAN is a solution for injection that contains the active substance ioflupane (123I).
Estonian: DaTSCAN on süstelahus, mille toimeaine on ioflupaan ().
English: • dementia (loss of intellectual function).
Estonian: • dementsus (vaimsete võimete nõrgenemine): DaTSCANi kasutatakse Lewy kehadega dementsuse eristamiseks Alzheimeri tõvest.
English: In dementia, the sensitivity of DaTSCAN in distinguishing dementia caused by Lewy bodies from other types of dementia ranged from 75 to 80%.
Estonian: DaTSCANi tundlikkus tõenäolise Lewy kehadega dementsuse eristamisel muud liiki dementsusest oli
English: How is DaTSCAN used?
Estonian: Kuidas DaTSCAN toimib?
English: It is used to detect the loss of nerve cells in an area of the brain called the striatum, specifically the cells that release dopamine, a chemical messenger.
Estonian: DaTSCANi kasutatakse virgatsainet dopamiini vabastavate närvirakkude hävimise tuvastamiseks juttkehaks (striatum) nimetatavas ajupiirkonnas.
English: How does DaTSCAN work?
Estonian: Kuidas DaTSCANi kasutatakse?
English: Invented Name Strength Pharmaceutical Form
Estonian: Tugevus Ravimvorm Loomaliigid ManustamisviisPakend
English: If pain persists for more than 12 hours, the doctor should be consulted again.
Estonian: Kui valu püsib rohkem kui 12 tundi, tuleb pöörduda uuesti arsti poole.
English: Porcine circovirus vaccine (inactivated)
Estonian: Sigade tsirkoviiruse vaktsiin (inaktiveeritud)
English: Accidental injection may cause severe pain and swelling, particularly if injected into a joint or finger - this could result in the loss of the finger if prompt medical attention is not given.
Estonian: Juhuslik enesesüstimine võib põhjustada tugevat valu ja turset, eriti kui süstitakse liigesesse või sõrme, mis võib viia vigastatud sõrme kaotuseni, kui viivitamatult ei pöörduta arsti poole.
English: The full EPAR for Porcilis PCV ID can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Porcilis PCV ID kohta on ameti veebilehel: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Porcilis PCV ID's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Veterinaarravimite komitee järeldas, et Porcilis PCV ID kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas vaktsiini kasutamise Euroopa Liidus heaks kiita.
English: The vaccine does not contain any live PCV2 so that it cannot cause disease.
Estonian: Vaktsiin ei sisalda PCV2-nakkuse elustekitajaid, nii et see ei saa põhjustada haigestumist.
English: The European Commission granted a marketing authorisation valid throughout the EU for Porcilis PCV ID on 28 August 2015.
Estonian: Euroopa Komisjon andis Porcilis PCV ID müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 28. augustil 2015.
English: The laboratory studies showed that the vaccine had its full effect against PCV2 by two weeks and that protection lasted 23 weeks after vaccination.
Estonian: Laboriuuringutes selgus, et vaktsiini toimel tekkis täielik kaitse PCV2 vastu 2. nädalaks ja kaitse püsis 23 nädalat pärast vaktsineerimist.
English: The vaccine was first studied in a number of laboratory studies in pigs.
Estonian: Vaktsiini efektiivsust sigadel uuriti kõigepealt mitmes laboriuuringus.
English: PCV2 is recognised as the primary cause of post-weaning multisystemic wasting syndrome (PMWS), but is also associated with a number of other conditions collectively known as porcine circovirus disease in Europe (PCVD) e.g porcine respiratory disease complex (PRDC), enteritis, reproductive disorders.
Estonian: PCV2 on teadaolevalt võõrutusjärgse multisüsteemse kurnatuse sündroomi (PMWS) peamine põhjus, kuid seda on seostatud ka mitme muu haigusega, mille Euroopa koondnimetus on sigade tsirkoviirushaigus (PCVD), nt sigade respiratoorsete haiguste kompleks (PRDC), enteriit, sigimishäired.
English: PCV2 infection is widespread and nearly all pig herds are infected with PCV2.
Estonian: PCV2 infektsioon on ulatusliku levikuga ning peaaegu kõik seakarjad on PCV2-ga nakatunud.
English: The main measures of effectiveness were average daily weight gain in the finishing period (fattening pigs in the period prior to slaughter) and PCV2 viraemia (virus in the blood).
Estonian: Efektiivsuse põhinäitajad olid lõpuperioodi (tapmiseelne nuumaperiood) päevane kaaluiive ja PCV2 vireemia (viiruse esinemine veres).
English: The most common side effect with Porcilis PCV ID (seen in more than 1 in 10 pigs) is a short-lived local reaction with hard non-painful swellings up to 2 cm in diameter which disappear within about five weeks of vaccination.
Estonian: Porcilis PCV ID kõige sagedam kõrvalnäht (esinenud enam kui 1 seal 10st) on mööduv paikne reaktsioon koos kuni 2 cm läbimõõduga kõvade valutute tursetega, mis kaovad ligikaudu 5 nädala jooksul pärast vaktsineerimisest.
English: The withdrawal period for meat from pigs treated with Porcilis PCV ID is ‘zero' days, which means that there is no mandatory waiting time.
Estonian: Vaktsiiniga Porcilis PCV ID ravitud sigade liha keeluaeg on 0 päeva, mis tähendab, et keeluaega ei ole.
English: Porcilis PCV ID is an emulsion containing mineral oil.
Estonian: Porcilis PCV ID on mineraalõli sisaldav emulsioon.
English: Similarly PCV2 viraemia was significantly lower in the vaccinated pigs compared with non-vaccinated pigs.
Estonian: Ka PCV2 vireemiat esines vaktsineeritud sigadel oluliselt vähem kui vaktsineerimata sigadel.
English: The vaccine is given using a suitable needle-free device for injection into the skin.
Estonian: Vaktsiin manustatakse sobiva nõelata süstimisseadme abil nahka.
English: Safety information has been included in the summary of product characteristics and the package leaflet for Porcilis PCV ID, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
Estonian: Ravimi omaduste kokkuvõttesse ja pakendi infolehele lisati Porcilis PCV ID ohutusteave, kus on ka tervishoiuspetsialistide ja loomaomanike või -pidajate võetavad meetmed.
English: What is Porcilis PCV ID and what is it used for?
Estonian: Mis on Porcilis PCV ID ja milleks seda kasutatakse?
English: This will help reduce the PCV2 viraemia, virus load in the lungs and lymphoid tissue and virus shedding.
Estonian: See aitab vähendada PCV2 infektsiooni põhjustatud vireemiat, viiruskoormust kopsudes ja lümfoidkoes ning viiruse eritumist.
English: It will also help to reduce the loss of daily weight gain and mortality associated with PCV2 infection.
Estonian: Samuti aitab see vähendada PCV2 infektsiooniga seotud päevase kaaluiibe langust ja suremust.
English: In all three studies average daily weight gain in the finishing period was significantly higher in the pigs vaccinated with Porcilis PCV ID compared with the non-vaccinated pigs.
Estonian: Kõigis kolmes uuringus oli vaktsiiniga Porcilis PCV ID vaktsineeritud sigade päevane kaaluiive lõpuperioodil oluliselt suurem kui vaktsineerimata sigadel.
English: The vaccine is used to reduce viraemia (presence of the virus in the blood), virus load in the lungs and lymphoid tissues and virus shedding.
Estonian: Vaktsiini kasutatakse vireemia (viirusveresuse esinemine veres), kopsude ja lümfoidkoe viiruskoormuse ning viiruse eritumise vähendamiseks.
English: For practical information about using Porcilis PCV ID, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Estonian: Kui loomaomanikud või -pidajad vajavad Porcilis PCV ID kasutamise praktilisi nõuandeid, peavad nad lugema pakendi infolehte või pöörduma oma veterinaararsti või apteekri poole.
English: Porcilis PCV ID is a vaccine.
Estonian: Porcilis PCV ID on vaktsiin.
English: Porcilis PCV ID has also been investigated in three field studies involving pig farms where PCV2 infection was present.
Estonian: Vaktsiini Porcilis PCV ID on uuritud ka kolmes väliuuringus, mis toimusid PCV2 infektsiooniga seafarmides.
English: When Porcilis PCV ID is given to pigs, the animals' immune system recognises the virus protein as ‘foreign' and reacts by building up an active immune response.
Estonian: Kui seale antakse vaktsiini Porcilis PCV ID, peab sea immuunsüsteem viirusevalku võõraks ja tekitab sellele reaktsioonina immuunvastuse.